IMPACT Career Development awardee Andrew Kiselica, Tech-AiD, weighed in on the impact of a mild cognitive impairment diagnosis, and ways to manage symptoms and slow progression in a recent opinion piece in the New York Times. Kiselica is an assistant professor of health psychology and a board-certified clinical neuropsychologist at the University of Missouri. He commented on the possibility of new dementia medications and current risks and benefits.
Building the nation’s capacity to conduct pragmatic clinical trials embedded within healthcare systems for people living with dementia and their care partners